tradingkey.logo
tradingkey.logo

Sol Gel Technologies Ltd

SLGL
67.790USD
-9.960-12.81%
Handelsschluss 03/30, 16:00ETKurse um 15 Minuten verzögert
121.92MMarktkapitalisierung
VerlustKGV TTM

Sol Gel Technologies Ltd

67.790
-9.960-12.81%

mehr Informationen über Sol Gel Technologies Ltd Unternehmen

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Sol Gel Technologies Ltd Informationen

BörsenkürzelSLGL
Name des UnternehmensSol Gel Technologies Ltd
IPO-datumFeb 01, 2018
CEO- -
Anzahl der mitarbeiter34
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 01
AddresseGolda Meir 7
StadtNESS-ZIONA
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl- -
Telefon97289313433
Websitehttp://www.sol-gel.com
BörsenkürzelSLGL
IPO-datumFeb 01, 2018
CEO- -

Führungskräfte von Sol Gel Technologies Ltd

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+73.38%
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Mr. Jerrold S. Gattegno
Mr. Jerrold S. Gattegno
Independent Director and External
Independent Director and External
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Mr. Nissim Bilman
Mr. Nissim Bilman
Vice President - Quality
Vice President - Quality
--
--
Mr. Jonathan B. Siegel
Mr. Jonathan B. Siegel
Independent Director
Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+73.38%
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Mr. Jerrold S. Gattegno
Mr. Jerrold S. Gattegno
Independent Director and External
Independent Director and External
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Mr. Nissim Bilman
Mr. Nissim Bilman
Vice President - Quality
Vice President - Quality
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sun, Mar 29
Aktualisiert: Sun, Mar 29
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
M.Arkin Dermatology, Ltd.
55.68%
Opaleye Management Inc.
14.18%
Phoenix Investment and Finances Ltd
6.72%
Arkin (Moshe)
4.41%
Yelin Lapidot Provident Funds Management Ltd
0.55%
Andere
18.45%
Aktionäre
Aktionäre
Anteil
M.Arkin Dermatology, Ltd.
55.68%
Opaleye Management Inc.
14.18%
Phoenix Investment and Finances Ltd
6.72%
Arkin (Moshe)
4.41%
Yelin Lapidot Provident Funds Management Ltd
0.55%
Andere
18.45%
Aktionärstypen
Aktionäre
Anteil
Corporation
55.68%
Hedge Fund
14.38%
Investment Advisor
7.58%
Individual Investor
4.46%
Insurance Company
0.23%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.06%
Andere
17.45%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
35
634.85K
22.79%
-440.31K
2025Q3
35
286.02K
10.27%
-480.14K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Opaleye Management Inc.
383.58K
13.77%
+10.43K
+2.80%
Dec 17, 2025
Phoenix Investment and Finances Ltd
218.22K
7.83%
-28.80K
-11.66%
Sep 30, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Menora Mivtachim Insurance Ltd.
7.61K
0.27%
+7.61K
--
Sep 30, 2025
Raymond James Financial Services Advisors, Inc.
--
0%
-7.81K
-100.00%
Sep 30, 2025
Morgan Stanley & Co. LLC
4.37K
0.16%
-970.00
-18.18%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
May 01, 2025
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
May 01, 2025
Merger
10→1
KeyAI